1. Home
  2. CET vs ADMA Comparison

CET vs ADMA Comparison

Compare CET & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

SELL

Current Price

$55.79

Market Cap

1.7B

Sector

Finance

ML Signal

SELL

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$11.06

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
ADMA
Founded
1929
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
CET
ADMA
Price
$55.79
$11.06
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
21.1K
★ 2.7M
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 4.87%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.35
Revenue
N/A
★ $42,219,783.00
Revenue This Year
N/A
$4.93
Revenue Next Year
N/A
$17.59
P/E Ratio
★ $6.93
$30.50
Revenue Growth
N/A
★ 43.85
52 Week Low
$47.82
$7.21
52 Week High
$57.39
$20.46

Technical Indicators

Market Signals
Indicator
CET
ADMA
Relative Strength Index (RSI) 52.17 70.67
Support Level $55.07 $9.23
Resistance Level $57.16 $11.42
Average True Range (ATR) 0.66 0.36
MACD -0.09 0.08
Stochastic Oscillator 47.74 93.09

Price Performance

Historical Comparison
CET
ADMA

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: